Breaking News

Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

Extensive panel of consented patient samples and iPSC technology designed to advance AD drug development and patient stratification.

Axol Bioscience Ltd., a pluripotent stem cell technology provider for drug discovery, entered into an agreement with StrataStem, a research-led biotechnology company, to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide range of brain cells, including neurons and neuroinflammatory cells. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters